Treventis Corporation

Michael D Carter

Donald F Weaver

Christopher J Barden

Erhu Lu

Mark A Reed

Shengguo Sun

Arun Yadav

Sheila Marie H Jacobo

Fuye Gao

Methods for identifying compounds that are inhibitors or are likely to be inhibitors of amyloid protein aggregation, as well as three-dimensional, non-crystallographic models (i.e. 'pseudo-crystal structures') of amyloid aggregation utilized in the methods, are described. Means for creating the three-dimensional, non-crystallographic models (i.e. 'pseudo-crystal structures') of amyloid aggregation are also described.

Methods for identifying inhibitors of amyloid protein aggregation

The present invention is directed to compounds that inhibit amyloid aggregation and methods of treatment therewith.

Methods of treating amyloid disease using analogs of 1-(4-nitrophenyl) piperazine

The invention is directed to compounds and methods for treating protein folder disorders. In certain embodiments the invention provides compounds and methods for treating neurodegenerative diseases such as Alzheimer's disease, tauopathy, cerebral amyloid angiopathy, Lewy body disease, dementia, Huntington's disease and prion-based spongiform encelopathy. The invention further provides compounds, methods and pharmaceutical compositions for inhibiting tau protein, A&#x3b2; protein or &#x3b1;-synuclein protein aggregation.

Compounds and methods for treating protein folding disorders

Growing community of inventors

Toronto, Canada

Michael D Carter